US › Healthcare

Rhythm Pharmaceuticals Inc (RYTM)

US · Healthcare · Biotechnology

$105.78+2.92%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$60.1M
Revenue YoY
+83.8%
Net profit
$-55.6M
Profit YoY
-12.4%
EPS
$-0.83
EPS estimate
$-0.86
Net margin
-92.6%

EPS came in at -0.83 against a street estimate of -0.86 — a beat of 3.5%.

Key statistics

Market cap
$7.05B
Forward P/E
0.0
P/B
55.42
Book value
$1.80
EPS (TTM)
$-3.13
52-week high
$122.20
52-week low
$74.50
50-day MA
$99.97
200-day MA
$99.03
Beta
1.97

Analyst view

Analysts rate Rhythm Pharmaceuticals Inc a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $138.80.

Shareholding

Insiders
0.77%
Institutions
110.28%

Largest institutional holders

FundStake
RA Capital Management, LLC9.73%
BlackRock Inc9.10%
Vanguard Group Inc9.06%
Baker Bros Advisors LP8.18%
PRIMECAP Management Company4.99%
Vanguard Portfolio Management, LLC4.44%
Vanguard Capital Management, LLC4.33%
Perceptive Advisors LLC3.46%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Rhythm Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.